Stockreport

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the batoclimab Myasthenia G [Read more]